Expensive cancer drugs are all the rage in pharma these days<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Growing evidence that healthcare research should not be entrusted to Big Pharma: In the last decade, the average cost of a brand-name cancer drug jumped from about $5,000 per month to $10,000 per month in 2013, according to a new IMS Institute for Healthcare Informatics study out this morning. Oncology, by far, remains the largest … <\/p>\n
Continue reading “Expensive cancer drugs are all the rage in pharma these days”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[51],"tags":[429,562,3484],"class_list":["post-9773","post","type-post","status-publish","format-standard","hentry","category-general","tag-big-pharma","tag-cancer-research","tag-treatment-cost"],"yoast_head":"\nExpensive cancer drugs are all the rage in pharma these days - the patient investor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expensive cancer drugs are all the rage in pharma these days - the patient investor\" \/>\n<meta property=\"og:description\" content=\"Growing evidence that healthcare research should not be entrusted to Big Pharma: In the last decade, the average cost of a brand-name cancer drug jumped from about $5,000 per month to $10,000 per month in 2013, according to a new IMS Institute for Healthcare Informatics study out this morning. Oncology, by far, remains the largest … Continue reading "Expensive cancer drugs are all the rage in pharma these days"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/\" \/>\n<meta property=\"og:site_name\" content=\"the patient investor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-06T17:49:39+00:00\" \/>\n<meta name=\"author\" content=\"ColinTwiggs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ColinTwiggs\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/05\\\/06\\\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/05\\\/06\\\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\\\/\"},\"author\":{\"name\":\"ColinTwiggs\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/cb072791ac83e8bae585007c133d54a5\"},\"headline\":\"Expensive cancer drugs are all the rage in pharma these days\",\"datePublished\":\"2014-05-06T17:49:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/05\\\/06\\\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\\\/\"},\"wordCount\":103,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"keywords\":[\"big pharma\",\"cancer research\",\"treatment cost\"],\"articleSection\":[\"General\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/05\\\/06\\\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/05\\\/06\\\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\\\/\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/05\\\/06\\\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\\\/\",\"name\":\"Expensive cancer drugs are all the rage in pharma these days - the patient investor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\"},\"datePublished\":\"2014-05-06T17:49:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/05\\\/06\\\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/05\\\/06\\\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/05\\\/06\\\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/thepatientinvestor.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Expensive cancer drugs are all the rage in pharma these days\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"name\":\"The Patient Investor\",\"description\":\"Smart. Strategic. Unfiltered. \",\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/thepatientinvestor.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\",\"name\":\"The Patient Investor Pty Ltd\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"width\":250,\"height\":250,\"caption\":\"The Patient Investor Pty Ltd\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61572934660810\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/cb072791ac83e8bae585007c133d54a5\",\"name\":\"ColinTwiggs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"caption\":\"ColinTwiggs\"},\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/author\\\/colin58s\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expensive cancer drugs are all the rage in pharma these days - the patient investor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Expensive cancer drugs are all the rage in pharma these days - the patient investor","og_description":"Growing evidence that healthcare research should not be entrusted to Big Pharma: In the last decade, the average cost of a brand-name cancer drug jumped from about $5,000 per month to $10,000 per month in 2013, according to a new IMS Institute for Healthcare Informatics study out this morning. Oncology, by far, remains the largest … Continue reading \"Expensive cancer drugs are all the rage in pharma these days\"","og_url":"https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/","og_site_name":"the patient investor","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61572934660810","article_published_time":"2014-05-06T17:49:39+00:00","author":"ColinTwiggs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ColinTwiggs"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/#article","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/"},"author":{"name":"ColinTwiggs","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5"},"headline":"Expensive cancer drugs are all the rage in pharma these days","datePublished":"2014-05-06T17:49:39+00:00","mainEntityOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/"},"wordCount":103,"commentCount":0,"publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"keywords":["big pharma","cancer research","treatment cost"],"articleSection":["General"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/","url":"https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/","name":"Expensive cancer drugs are all the rage in pharma these days - the patient investor","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/#website"},"datePublished":"2014-05-06T17:49:39+00:00","breadcrumb":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/05\/06\/expensive-cancer-drugs-are-all-the-rage-in-pharma-these-days\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepatientinvestor.com\/"},{"@type":"ListItem","position":2,"name":"Expensive cancer drugs are all the rage in pharma these days"}]},{"@type":"WebSite","@id":"https:\/\/thepatientinvestor.com\/#website","url":"https:\/\/thepatientinvestor.com\/","name":"The Patient Investor","description":"Smart. Strategic. Unfiltered. ","publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepatientinvestor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepatientinvestor.com\/#organization","name":"The Patient Investor Pty Ltd","url":"https:\/\/thepatientinvestor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","width":250,"height":250,"caption":"The Patient Investor Pty Ltd"},"image":{"@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61572934660810","https:\/\/www.instagram.com\/colin_thepatientinvestor"]},{"@type":"Person","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5","name":"ColinTwiggs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","caption":"ColinTwiggs"},"url":"https:\/\/thepatientinvestor.com\/index.php\/author\/colin58s\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9tQ4n-2xD","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":9721,"url":"https:\/\/thepatientinvestor.com\/index.php\/2014\/04\/24\/how-big-pharma-holds-back-in-the-war-on-cancer-the-daily-beast\/","url_meta":{"origin":9773,"position":0},"title":"How Big Pharma Holds Back in the War on Cancer – The Daily Beast","author":"ColinTwiggs","date":"April 24, 2014","format":false,"excerpt":"From Jake Bernstein at ProPublica: Take Michelle Holmes, an associate professor of medicine at Harvard Medical School. She\u2019s been trying for years to raise money for trials on the effects of aspirin on breast cancer. Animal studies, in vitro experiments and analysis of patient outcomes suggest that aspirin might help\u2026","rel":"","context":"In "Interests"","block_context":{"text":"Interests","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/interests\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":24141,"url":"https:\/\/thepatientinvestor.com\/index.php\/2021\/02\/17\/seagen-inc-sgen\/","url_meta":{"origin":9773,"position":1},"title":"Seagen Inc. (SGEN)","author":"Colin Twiggs","date":"February 17, 2021","format":false,"excerpt":"Stock: Seagen Inc. Exchange: Nasdaq Symbol: SGEN Date: 16-Feb-21 Latest price: 159.34 USD Market Cap: $28.8 bn Fair Value: 103.59 Forward P\/E: n\/a FV Payback: 10 Years Forward Dividend Yield: - Nil - Debt\/Equity: - Nil - Financial Y\/E: 31-Dec-21 Rating: HOLD Sector: Health Care Industry: Biotechnology Investment Theme: LT\u2026","rel":"","context":"In "International Growth"","block_context":{"text":"International Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/international-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":12189,"url":"https:\/\/thepatientinvestor.com\/index.php\/2015\/08\/17\/why-we-need-to-end-the-war-on-drugs-ted\/","url_meta":{"origin":9773,"position":2},"title":"Why we need to end the War on Drugs | TED","author":"ColinTwiggs","date":"August 17, 2015","format":false,"excerpt":"\u00a0 \"Prohibition is not the ultimate in regulation \u2014 it is the abdication of regulation.\" Is the War on Drugs doing more harm than good? In a bold talk, drug policy reformist Ethan Nadelmann makes an impassioned plea to end the \"backward, heartless, disastrous\" movement to stamp out the drug\u2026","rel":"","context":"In "The Big Picture"","block_context":{"text":"The Big Picture","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/the-big-picture\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":6431,"url":"https:\/\/thepatientinvestor.com\/index.php\/2012\/12\/10\/portuguese-drug-policy-shows-that-decriminalisation-can-work-but-only-with-other-policies-europp\/","url_meta":{"origin":9773,"position":3},"title":"Portuguese drug policy shows that decriminalisation can work, but only with other policies. | EUROPP","author":"Colin Twiggs","date":"December 10, 2012","format":false,"excerpt":"Alex Stevens writes on decriminalizing drug use: International analysis, both by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and in my book Drugs, Crime and Public Health suggests there is little correlation between the level of punishment for drug offences and the rate of drug use or\u2026","rel":"","context":"In "The Big Picture"","block_context":{"text":"The Big Picture","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/the-big-picture\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14045,"url":"https:\/\/thepatientinvestor.com\/index.php\/2016\/08\/27\/portugal-what-happened-after-it-decriminalized-drugs-vice\/","url_meta":{"origin":9773,"position":4},"title":"Portugal: What Happened After It Decriminalized Drugs | VICE","author":"ColinTwiggs","date":"August 27, 2016","format":false,"excerpt":"By Samuel Oakford .....16 years ago, Portugal took a leap and decriminalized the possession of all drugs \u2014 everything from marijuana to heroin. By most measures, the move has paid off. The rate of new HIV infections in Portugal has fallen precipitously since 2001, the year its law took effect,\u2026","rel":"","context":"In "The Big Picture"","block_context":{"text":"The Big Picture","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/the-big-picture\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":17181,"url":"https:\/\/thepatientinvestor.com\/index.php\/2018\/10\/22\/clinuvel-pharmaceuticals-limited-cuv\/","url_meta":{"origin":9773,"position":5},"title":"Clinuvel Pharmaceuticals Limited (CUV)","author":"Colin Twiggs","date":"October 22, 2018","format":false,"excerpt":"Stock: Clinuvel Pharmaceuticals Limited Symbol: CUV Exchange: ASX Latest Price: $18.71 Market cap: $900 million Currency: AUD Financial Year: 30 June Date: 22 October 2018 Sector: Healthcare Industry: Biotechnology Investment Theme: Long-term Growth Structural Trends: Advances in medical treatment of genetic disorders. Company Profile Clinuvel develops drugs for treatment of\u2026","rel":"","context":"In "Australian Growth"","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"CUV Development Pipeline","src":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2018\/10\/cuv-product-pipeline-fy18.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2018\/10\/cuv-product-pipeline-fy18.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2018\/10\/cuv-product-pipeline-fy18.png?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/9773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/comments?post=9773"}],"version-history":[{"count":0,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/9773\/revisions"}],"wp:attachment":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/media?parent=9773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/categories?post=9773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/tags?post=9773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}